JUNSHealthcare · BiotechnologyJUNS Stock Forecast: Jupiter Neurosciences, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 13 of 100 as at 1 Aug 2026 — in the weakest quartile.
JUNS stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Jupiter Neurosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (96): Smaller than most of the companies we track.
Quality (6): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
The rank is the raw material. Whether the rules would actually own Jupiter Neurosciences, Inc. — and when they’d sell — is the membership.
JUNS stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on JUNS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
JUNS analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Jupiter Neurosciences, Inc. (JUNS) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −0.4×
- Price / sales
- 125.8×
- Price / book
- −1.2×
- EV / EBITDA
- −0.7×
Cheaper than 79% of US stocks
Cheaper than 3% of US stocks
Cheaper than 94% of US stocks
Cheaper than 66% of US stocks
- Revenue growth (YoY)
- −14.4%
- Earnings growth (YoY)
- —
- Gross margin
- 76.6%
- Operating margin
- −10524.3%
- Net margin
- 80.6%
Higher than 13% of US stocks
Higher than 89% of US stocks
Higher than 2% of US stocks
Higher than 98% of US stocks
- Return on equity
- −6529.2%
- Return on assets
- −130.9%
- Dividend yield
- —
Higher than 1% of US stocks
Higher than 2% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
JUNS vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. JUNS appears on the weeks it earns a place.
Frequently asked questions about JUNS stock
Is JUNS stock a buy right now?
Of the 1 analysts covering Jupiter Neurosciences, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Jupiter Neurosciences, Inc. 13 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank JUNS?
As at 1 Aug 2026, Jupiter Neurosciences, Inc. ranks 13 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (96 of 100).
What is the JUNS stock forecast for 2030?
No analyst covering Jupiter Neurosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for JUNS are extrapolating price history, which says nothing about the business.
How has JUNS stock performed over the past year?
Jupiter Neurosciences, Inc. returned -92.6% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Jupiter Neurosciences, Inc. do?
Jupiter Neurosciences Inc. is a clinical-stage pharmaceutical company focused on developing therapies for neuroinflammation and related central nervous system disorders.
About Jupiter Neurosciences, Inc.
Jupiter Neurosciences Inc. is a clinical-stage pharmaceutical company focused on developing therapies for neuroinflammation and related central nervous system disorders. Based in Jupiter, Florida and founded in 2015, the company is built around a proprietary resveratrol-based drug platform designed to deliver this compound in a more effective and bioavailable oral form. Its lead product candidate, JOTROL, targets a broad range of conditions where neuroinflammation is a key component, including various neurodegenerative and rare diseases. Jupiter Neurosciences also integrates its platform into consumer-oriented longevity and wellness formulations under the Nugevia brand, addressing areas such as mitochondrial support, cognitive health, and skin vitality. Operating within the healthcare and biotechnology sectors, the company primarily serves unmet medical needs in CNS and rare disease markets, positioning its resveratrol platform at the intersection of clinical therapeutics and scientifically grounded wellness solutions.
CEO Mr. Christer Rosen · 5 employees · United States · https://jupiterneurosciences.com